To examine the variability in the real-world care of relapsed/refractory multiple myeloma in China.
Conducted a physician survey to gather data on treatment practices
Analyzed responses to assess variability in management strategies
Explored the need for evidence-based guidelines
Identified significant variability in the management of relapsed/refractory multiple myeloma
Highlights the gap in standardized care practices
Emphasizes the importance of ongoing research for improving patient outcomes.
Abstract
Real-world management of relapsed/refractory MM in China is highly variable. These findings highlight the necessity for ongoing research and evidence-based guidelines to optimize patient outcomes.